Update on the current use of hormonals as therapy in advanced breast cancer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hormonal agents have a confirmed role in the management of postmenopausal women with receptor-positive advanced breast cancer. Until recently, tamoxifen has been the accepted agent for treating these patients. However, accumulating evidence suggests that the new antiaromatase agents will replace the antiestrogens as the preferable option in hormone-naive patients. Comparative trials indicate that the aromatase inhibitors, anastrozole and letrozole, and the aromatase inactivator, exemestane, have at least equivalent efficacy to tamoxifen with similar or superior tolerability. These agents are also more effective than the progestin, megestrol acetate, when studied in patients progressing on tamoxifen. The improved aromatase selectivity and high potency of these antiaromatase agents when compared with earlier agents have resulted in improved efficacy and tolerability. Additionally, no cross-resistance has been reported between the antiaromatase agents and tamoxifen or, in some instances, among the antiaromatase agents themselves. The role of antiaromatase agents will certainly expand in the near future to include not only treatment of metastatic breast cancer, but use in the adjuvant and neoadjuvant settings as well, and, ultimately, breast cancer prevention. The results of ongoing investigations are awaited with interest.

Original languageEnglish
Pages (from-to)265-273
Number of pages9
JournalAnti-Cancer Drugs
Volume14
Issue number4
DOIs
StatePublished - Apr 1 2003
Externally publishedYes

Fingerprint

Tamoxifen
Breast Neoplasms
exemestane
Aromatase
letrozole
Megestrol Acetate
Aromatase Inhibitors
Estrogen Receptor Modulators
Proxy
Progestins
Therapeutics
Hormones

Keywords

  • Antiaromatase agents
  • Breast cancer
  • Exemestane
  • Hormonal therapy

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Update on the current use of hormonals as therapy in advanced breast cancer. / Vogel, Charles.

In: Anti-Cancer Drugs, Vol. 14, No. 4, 01.04.2003, p. 265-273.

Research output: Contribution to journalArticle

@article{f737d23330e14dc382c7a8e08c9c4e7a,
title = "Update on the current use of hormonals as therapy in advanced breast cancer",
abstract = "Hormonal agents have a confirmed role in the management of postmenopausal women with receptor-positive advanced breast cancer. Until recently, tamoxifen has been the accepted agent for treating these patients. However, accumulating evidence suggests that the new antiaromatase agents will replace the antiestrogens as the preferable option in hormone-naive patients. Comparative trials indicate that the aromatase inhibitors, anastrozole and letrozole, and the aromatase inactivator, exemestane, have at least equivalent efficacy to tamoxifen with similar or superior tolerability. These agents are also more effective than the progestin, megestrol acetate, when studied in patients progressing on tamoxifen. The improved aromatase selectivity and high potency of these antiaromatase agents when compared with earlier agents have resulted in improved efficacy and tolerability. Additionally, no cross-resistance has been reported between the antiaromatase agents and tamoxifen or, in some instances, among the antiaromatase agents themselves. The role of antiaromatase agents will certainly expand in the near future to include not only treatment of metastatic breast cancer, but use in the adjuvant and neoadjuvant settings as well, and, ultimately, breast cancer prevention. The results of ongoing investigations are awaited with interest.",
keywords = "Antiaromatase agents, Breast cancer, Exemestane, Hormonal therapy",
author = "Charles Vogel",
year = "2003",
month = "4",
day = "1",
doi = "10.1097/00001813-200304000-00003",
language = "English",
volume = "14",
pages = "265--273",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Update on the current use of hormonals as therapy in advanced breast cancer

AU - Vogel, Charles

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Hormonal agents have a confirmed role in the management of postmenopausal women with receptor-positive advanced breast cancer. Until recently, tamoxifen has been the accepted agent for treating these patients. However, accumulating evidence suggests that the new antiaromatase agents will replace the antiestrogens as the preferable option in hormone-naive patients. Comparative trials indicate that the aromatase inhibitors, anastrozole and letrozole, and the aromatase inactivator, exemestane, have at least equivalent efficacy to tamoxifen with similar or superior tolerability. These agents are also more effective than the progestin, megestrol acetate, when studied in patients progressing on tamoxifen. The improved aromatase selectivity and high potency of these antiaromatase agents when compared with earlier agents have resulted in improved efficacy and tolerability. Additionally, no cross-resistance has been reported between the antiaromatase agents and tamoxifen or, in some instances, among the antiaromatase agents themselves. The role of antiaromatase agents will certainly expand in the near future to include not only treatment of metastatic breast cancer, but use in the adjuvant and neoadjuvant settings as well, and, ultimately, breast cancer prevention. The results of ongoing investigations are awaited with interest.

AB - Hormonal agents have a confirmed role in the management of postmenopausal women with receptor-positive advanced breast cancer. Until recently, tamoxifen has been the accepted agent for treating these patients. However, accumulating evidence suggests that the new antiaromatase agents will replace the antiestrogens as the preferable option in hormone-naive patients. Comparative trials indicate that the aromatase inhibitors, anastrozole and letrozole, and the aromatase inactivator, exemestane, have at least equivalent efficacy to tamoxifen with similar or superior tolerability. These agents are also more effective than the progestin, megestrol acetate, when studied in patients progressing on tamoxifen. The improved aromatase selectivity and high potency of these antiaromatase agents when compared with earlier agents have resulted in improved efficacy and tolerability. Additionally, no cross-resistance has been reported between the antiaromatase agents and tamoxifen or, in some instances, among the antiaromatase agents themselves. The role of antiaromatase agents will certainly expand in the near future to include not only treatment of metastatic breast cancer, but use in the adjuvant and neoadjuvant settings as well, and, ultimately, breast cancer prevention. The results of ongoing investigations are awaited with interest.

KW - Antiaromatase agents

KW - Breast cancer

KW - Exemestane

KW - Hormonal therapy

UR - http://www.scopus.com/inward/record.url?scp=0038243777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038243777&partnerID=8YFLogxK

U2 - 10.1097/00001813-200304000-00003

DO - 10.1097/00001813-200304000-00003

M3 - Article

C2 - 12679730

AN - SCOPUS:0038243777

VL - 14

SP - 265

EP - 273

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 4

ER -